Verastem Inc. is reducing its workforce by approximately 50% to 20 full time employees. The company suffered a blow on September 28, 2015, with the stock losing 67% of its value, following an enrollment halt to a phase II study of its lead drug candidate VS-6063 for patients with mesothelioma due to futility.